Itch reduction was evaluated as a key secondary endpoint in randomized, double-blind, placebo-controlled trials: 3 adult trials, 1 trial in adolescents (12-17 years of age), 1 trial in children (6-11 years of age), 1 trial in infants to preschoolers (6 months to 5 years of age) with uncontrolled moderate-to-severe atopic dermatitis, and 1 trial in atopic dermatitis patients (12 years and older) with uncontrolled moderate-to-severe hand and/or foot involvement.1,2 Click here for additional clinical trial design information.
Itch reduction with DUPIXENT was rapid and sustained in adults at 52 weeks. In SOLO 1, a significantly greater proportion of adult patients had improvement on the Peak Pruritus NRS score vs placebo (defined as at least a 4-point improvement) as early as Week 2 (9% of DUPIXENT patients achieved ≥4-point reduction in NRS score at Week 2 vs 3% with placebo [P=0.0097]).1,2
In addition, in CHRONOS1,4:
Improvement in Peak Pruritus NRS observed in adolescents treated with DUPIXENT (defined as ≥4-point improvement) as early as Week 4 (22% with DUPIXENT vs 5% with placebo; nominal P<0.001).5
Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal.
Improvement in Worst Scratch/Itch NRS observed in infants to preschoolers treated with DUPIXENT + TCS compared with placebo (defined as ≥4-point improvement) at Week 3 (22% with DUPIXENT + TCS vs 4% with placebo + TCS).1,2
Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal.
A greater proportion of atopic dermatitis patients aged 12+ years with uncontrolled moderate-to-severe hand and/or foot involvement treated with DUPIXENT achieved an improvement in the hand and foot Peak Pruritus NRS at Week 16 compared with placebo (defined as ≥4-point improvement).1,8